Asset Details
Do you wish to reserve the book?
Evaluating drug targets through human loss-of-function genetic variation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Evaluating drug targets through human loss-of-function genetic variation
Do you wish to request the book?
Evaluating drug targets through human loss-of-function genetic variation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Evaluating drug targets through human loss-of-function genetic variation
2020
Overview
Naturally occurring human genetic variants that are predicted to inactivate protein-coding genes provide an in vivo model of human gene inactivation that complements knockout studies in cells and model organisms. Here we report three key findings regarding the assessment of candidate drug targets using human loss-of-function variants. First, even essential genes, in which loss-of-function variants are not tolerated, can be highly successful as targets of inhibitory drugs. Second, in most genes, loss-of-function variants are sufficiently rare that genotype-based ascertainment of homozygous or compound heterozygous ‘knockout’ humans will await sample sizes that are approximately 1,000 times those presently available, unless recruitment focuses on consanguineous individuals. Third, automated variant annotation and filtering are powerful, but manual curation remains crucial for removing artefacts, and is a prerequisite for recall-by-genotype efforts. Our results provide a roadmap for human knockout studies and should guide the interpretation of loss-of-function variants in drug development.
Analysis of predicted loss-of-function variants from 125,748 human exomes and 15,708 whole genomes in the Genome Aggregation Database (gnomAD) provides a roadmap for human ‘knockout’ studies and a guide for future research into disease biology and drug-target selection.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ 45/23
/ Analysis
/ Biologi
/ Disease
/ Drugs
/ Gain of Function Mutation - genetics
/ Genes
/ Genes, Essential - drug effects
/ Humanities and Social Sciences
/ Humans
/ Huntingtin Protein - genetics
/ Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 - genetics
/ Loss of Function Mutation - genetics
/ Medical Genetics and Genomics (including Gene Therapy)
/ Medicinsk genetik och genomik (Här ingår: Genterapi)
/ Medicinska och farmaceutiska grundvetenskaper
/ Mutation
/ Neurodegenerative Diseases - genetics
/ Proteins
/ Science
